Understanding Ulcerative Colitis
Ulcerative colitis, often called UC, is a chronic inflammatory bowel disease that affects the lining of the colon and rectum. It can cause symptoms such as abdominal discomfort, diarrhea, rectal bleeding, urgency, fatigue, and reduced quality of life.
UC is closely connected to immune system imbalance. In people with UC, the immune system can remain overactive in the intestinal lining, leading to ongoing inflammation and damage to the gut barrier. Because of this, researchers are exploring therapies that may help calm inflammation, support immune balance, and promote healing of the intestinal lining.
One area of interest is the use of umbilical cord-derived mesenchymal stem cells, or UMSCs.
Why Researchers Are Studying UMSCs
UMSCs are being studied in regenerative medicine because they release signaling molecules that may influence inflammation, immune activity, and tissue repair.
For ulcerative colitis, this is especially important because the condition involves both immune overactivity and damage to the intestinal lining. A therapy that may help regulate the immune response while supporting mucosal healing could be valuable for future UC research.
This study focused especially on how UMSCs may affect T cells, which are immune cells that help coordinate inflammation. When T cells become overactive or imbalanced, they can contribute to chronic inflammation in the gut.
Study Overview
This clinical study included 26 patients with moderate to severe left-sided ulcerative colitis. Each patient received two intravenous UMSC infusions, given once per month. The dose was 1 × 10⁶ cells per kilogram of body weight.
Researchers followed patients for up to 6 months and evaluated:
- UC symptoms and clinical response
- Endoscopic findings in the colon
- Tissue inflammation
- Inflammatory markers
- Immune cell activity
A key part of the study was the use of single-cell RNA sequencing, a technology that allowed researchers to study individual immune cells from colon biopsy samples. This helped them better understand how UMSC therapy may affect immune activity at the cellular level.
Key Findings
The study reported encouraging results after UMSC therapy. After 2 months, the clinical response rate was 80.8%, and the clinical remission rate was 46.2%. At 6 months, the clinical response rate was 75.0%, and the remission rate was 37.5%.
Researchers also observed improvements in the intestinal lining among patients who responded to treatment. Endoscopic and tissue evaluations showed reduced inflammation and improved mucosal appearance after therapy.
The study also found decreases in several inflammatory cytokines, including IL-1β, IL-6, IL-8, IL-12, and IL-17A. These cytokines are involved in inflammatory signaling, so reductions may suggest a calmer immune environment in the gut.
How UMSCs May Support Gut Healing
One of the most important findings was that UMSC therapy appeared to influence T cell-mediated immunity.
In simpler terms, UMSCs may help shift certain immune cells away from an overly inflammatory state. The single-cell analysis suggested that UMSC therapy reduced inflammatory communication between T cells, B cells, and myeloid cells.
This matters because ulcerative colitis is not only about inflammation itself, but also about how immune cells communicate within the intestinal tissue. By helping regulate this immune network, UMSCs may support a healthier gut environment and promote mucosal repair.
UMSCs may also support healing through paracrine signaling, which means they release helpful molecules that communicate with nearby cells. These signals may help reduce inflammation, support tissue repair, and protect the intestinal barrier.
Why This Research Matters
This study is meaningful because it connects clinical improvement with deeper immune-level changes. Researchers did not only look at symptoms; they also studied how immune cells behaved before and after therapy.
The findings suggest that UMSCs may support ulcerative colitis by helping rebalance immune activity, lowering inflammatory cytokines, and improving the condition of the intestinal lining.
For regenerative medicine, this study adds to the growing interest in MSC-based therapies for immune-related conditions. Rather than targeting only one inflammatory pathway, UMSCs may influence several repair and immune-regulating processes at once.
Looking Ahead
This study provides a promising foundation for continued research into UMSCs and ulcerative colitis. Future studies with larger patient groups and controlled trial designs can help confirm these findings, clarify long-term outcomes, and identify which patients may benefit most.
Tools like single-cell RNA sequencing may also help researchers better understand how regenerative therapies affect immune cell behavior and guide more personalized approaches in the future.
Takeaway
This study suggests that umbilical cord-derived mesenchymal stem cells may help support immune balance and gut repair in ulcerative colitis. Patients receiving UMSC therapy showed encouraging clinical response and remission rates, along with improvements in endoscopic findings, tissue inflammation, and inflammatory markers.
While more research is needed, these findings highlight an important direction in regenerative medicine: supporting the body’s repair environment by helping regulate immune activity and protect tissue function.
Source
Luo X, Deng J, Jiang X, Mi J, Bai Y, Zhang H, Li Y, Liu M, Cai C, Li P, Huang H, Xu Y, Qin Y, Mi Y, Ding H, Yang Z, Wu Y, Li Z, Lan L, Zhang L, Wang L, Chen G, Yue H, Luo OJ, Zhang B. Reconstitution of T cell-mediated immunity by umbilical cord-derived mesenchymal stem cells in ulcerative colitis. Clinical and Translational Medicine. 2025 Aug 21;15(8). doi: 10.1002/ctm2.70452. PMID: 40842289; PMCID: PMC12371211. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70452
Related Treatment Pages